Is the management of acute confusional syndrome secondary to covid-19 pneumonia different from the management of confusional syndrome secondary to other causes?
Introduction Acute Confusional Syndrome (ACS) is the most common neuropsychiatric complication in COVID-19 infection. Its management is still a challenge because the data and recommendations based on the evidence are limited. Objectives To describe the differential characteristics in the managemen...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2022-06-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822007878/type/journal_article |
| _version_ | 1797616613316362240 |
|---|---|
| author | A. Llimona González M. Calls Samora D. García Hernández S. Oller Canet |
| author_facet | A. Llimona González M. Calls Samora D. García Hernández S. Oller Canet |
| author_sort | A. Llimona González |
| collection | DOAJ |
| description |
Introduction
Acute Confusional Syndrome (ACS) is the most common neuropsychiatric complication in COVID-19 infection. Its management is still a challenge because the data and recommendations based on the evidence are limited.
Objectives
To describe the differential characteristics in the management of ACS in patients with COVID-19 pneumonia compared to ACS secondary to other causes.
Methods
We present a descriptive study that is has been carried out in 62 patients with ACS (26 of them diagnosed with COVID 19 pneumonia), who have required assessment by the liaison psychiatry service of Hospital del Mar between February and April, 2020. The sample was divided in 2 groups (with and without COVID 19 pneumonia). Chi square and Fisher’s tests were used to comparisons.
Results
Dexmetomidine (26 vs 0) and olanzapine (13 vs 3) were significantly more frequently used in COVID-19 patients (p< 0 001). A greater number of different antipsychotic drugs were used in COVID 19 patients (2.40± 1 323 number of drugs), (p<0.0001). Further neuroimaging tests were requested in COVID 19 patients and they received less family support (4) compared to non COVID-19 (22), (p<0.005).
Conclusions
ACS associated with COVID-19 pneumonia in the patients in our sample is more difficult to manage than ACS associated with other pathologies, similar to which described in other series. It is associated with a longer duration of confusional symptoms and difficulties for control it.
Disclosure
No significant relationships.
|
| first_indexed | 2024-03-11T07:43:45Z |
| format | Article |
| id | doaj.art-e80399c4ede84685b93714f9a745abed |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:43:45Z |
| publishDate | 2022-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-e80399c4ede84685b93714f9a745abed2023-11-17T05:08:13ZengCambridge University PressEuropean Psychiatry0924-93381778-35852022-06-0165S308S30810.1192/j.eurpsy.2022.787Is the management of acute confusional syndrome secondary to covid-19 pneumonia different from the management of confusional syndrome secondary to other causes?A. Llimona González0M. Calls Samora1D. García Hernández2S. Oller Canet3Parc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, SpainParc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, SpainParc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, SpainParc de Salut Mar, Instituto De Neuropsiquiatría Y Adicciones (inad), Barcelona, Spain Introduction Acute Confusional Syndrome (ACS) is the most common neuropsychiatric complication in COVID-19 infection. Its management is still a challenge because the data and recommendations based on the evidence are limited. Objectives To describe the differential characteristics in the management of ACS in patients with COVID-19 pneumonia compared to ACS secondary to other causes. Methods We present a descriptive study that is has been carried out in 62 patients with ACS (26 of them diagnosed with COVID 19 pneumonia), who have required assessment by the liaison psychiatry service of Hospital del Mar between February and April, 2020. The sample was divided in 2 groups (with and without COVID 19 pneumonia). Chi square and Fisher’s tests were used to comparisons. Results Dexmetomidine (26 vs 0) and olanzapine (13 vs 3) were significantly more frequently used in COVID-19 patients (p< 0 001). A greater number of different antipsychotic drugs were used in COVID 19 patients (2.40± 1 323 number of drugs), (p<0.0001). Further neuroimaging tests were requested in COVID 19 patients and they received less family support (4) compared to non COVID-19 (22), (p<0.005). Conclusions ACS associated with COVID-19 pneumonia in the patients in our sample is more difficult to manage than ACS associated with other pathologies, similar to which described in other series. It is associated with a longer duration of confusional symptoms and difficulties for control it. Disclosure No significant relationships. https://www.cambridge.org/core/product/identifier/S0924933822007878/type/journal_articledeliriumACUTE CONFUSIONAL COVID-19CONFUSIONALCovid-19 |
| spellingShingle | A. Llimona González M. Calls Samora D. García Hernández S. Oller Canet Is the management of acute confusional syndrome secondary to covid-19 pneumonia different from the management of confusional syndrome secondary to other causes? European Psychiatry delirium ACUTE CONFUSIONAL COVID-19 CONFUSIONAL Covid-19 |
| title | Is the management of acute confusional syndrome secondary to covid-19 pneumonia different from the management of confusional syndrome secondary to other causes? |
| title_full | Is the management of acute confusional syndrome secondary to covid-19 pneumonia different from the management of confusional syndrome secondary to other causes? |
| title_fullStr | Is the management of acute confusional syndrome secondary to covid-19 pneumonia different from the management of confusional syndrome secondary to other causes? |
| title_full_unstemmed | Is the management of acute confusional syndrome secondary to covid-19 pneumonia different from the management of confusional syndrome secondary to other causes? |
| title_short | Is the management of acute confusional syndrome secondary to covid-19 pneumonia different from the management of confusional syndrome secondary to other causes? |
| title_sort | is the management of acute confusional syndrome secondary to covid 19 pneumonia different from the management of confusional syndrome secondary to other causes |
| topic | delirium ACUTE CONFUSIONAL COVID-19 CONFUSIONAL Covid-19 |
| url | https://www.cambridge.org/core/product/identifier/S0924933822007878/type/journal_article |
| work_keys_str_mv | AT allimonagonzalez isthemanagementofacuteconfusionalsyndromesecondarytocovid19pneumoniadifferentfromthemanagementofconfusionalsyndromesecondarytoothercauses AT mcallssamora isthemanagementofacuteconfusionalsyndromesecondarytocovid19pneumoniadifferentfromthemanagementofconfusionalsyndromesecondarytoothercauses AT dgarciahernandez isthemanagementofacuteconfusionalsyndromesecondarytocovid19pneumoniadifferentfromthemanagementofconfusionalsyndromesecondarytoothercauses AT sollercanet isthemanagementofacuteconfusionalsyndromesecondarytocovid19pneumoniadifferentfromthemanagementofconfusionalsyndromesecondarytoothercauses |